Pharma

What to Watch in the Day Ahead - Friday, February 3

  • February 02, 2023 02:30 PM EST | Reuters
 What to Watch in the Day Ahead - Friday, February 3

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at. Thomson One users

Read More...
Medicure Announces Resignation Of Board Member And Grant Of Stock Options

Medicure Announces Resignation Of Board Member And Grant Of Stock Options

  • February 01, 2023 07:17 AM EST | Reuters

Feb 1 (Reuters) - Medicure Inc: * MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS Source text for Eikon: Further company coverage:

Read More...
Numinus Receives Clinical Trial Application Approval From Health Canada

Numinus Receives Clinical Trial Application Approval From Health Canada

  • February 01, 2023 07:11 AM EST | Reuters

Feb 1 (Reuters) - Numinus Wellness Inc: * NUMINUS RECEIVES CLINICAL TRIAL APPLICATION APPROVAL FROM HEALTH CANADA FOR EXPERIENTIAL PSYCHEDELIC-ASSISTED THERAPY TRAINING USING PSILOCYBE CUBENSIS TEA

Read More...
PRESS DIGEST-Canada - Feb 1

PRESS DIGEST-Canada - Feb 1

  • February 01, 2023 06:53 AM EST | Reuters

Feb 1 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL - The Alberta

Read More...
Recruiting Underway In Fsd Pharma's Phase 2 Trial Of Fsd-Pea For Treatment Of Chronic Pain Associated With Idiopathic Mcas

Recruiting Underway In Fsd Pharma's Phase 2 Trial Of Fsd-Pea For Treatment Of Chronic Pain Associated With Idiopathic Mcas

  • January 30, 2023 08:59 AM EST | Reuters

Jan 30 (Reuters) - FSD Pharma Inc: * RECRUITING UNDERWAY IN FSD PHARMA’S PHASE 2 TRIAL OF FSD-PEA (FSD201) FOR THE TREATMENT OF CHRONIC PAIN ASSOCIATED WITH IDIOPATHIC MCAS (MCAD) Source text for

Read More...
ESSA Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview

ESSA Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview

  • January 30, 2023 07:43 AM EST | Reuters

* ESSA Pharma Inc is expected to show no change in quarterly revenue when it reports results on February 1 (estimated). * * ​Refinitiv's mean analyst estimate for ESSA Pharma Inc is for a loss of 23

Read More...
ESSA Pharma Inc <EPIX.O>: A loss of 23 cents per share anticipated for fourth quarter

ESSA Pharma Inc <EPIX.O>: A loss of 23 cents per share anticipated for fourth quarter

  • January 30, 2023 07:42 AM EST | Reuters

30 January 2023 12:42 p.m. All figures in US dollars. ESSA Pharma Inc is expected to show a decrease in its fourth quarter earnings to -23 cents​ per share according to the mean Refinitiv estimate

Read More...
Microbix Launches QAP To Support “Monkeypox” Testing

Microbix Launches QAP To Support “Monkeypox” Testing

  • January 30, 2023 07:40 AM EST | Reuters

Jan 30 (Reuters) - Microbix Biosystems Inc: * MICROBIX LAUNCHES QAP TO SUPPORT “MONKEYPOX” TESTING Source text for Eikon: Further company coverage:

Read More...
Aptose Starts Dosing Of Tuspetinib In Patients With Acute Myeloid Leukemia

Aptose Starts Dosing Of Tuspetinib In Patients With Acute Myeloid Leukemia

  • January 30, 2023 07:30 AM EST | Reuters

Jan 30 (Reuters) - Aptose Biosciences Inc: * APTOSE INITIATES DOSING OF TUSPETINIB IN APTIVATE EXPANSION TRIAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA * APTOSE BIOSCIENCES INC-ANOTHER CLINICAL

Read More...
High Tide Inc expected to post a loss of 8 cents a share - Earnings Preview

High Tide Inc expected to post a loss of 8 cents a share - Earnings Preview

  • January 27, 2023 05:28 PM EST | Reuters

* High Tide Inc is expected to show a rise in quarterly revenue when it reports results on January 30. * The Calgary Alberta-based company is expected to report a 87.3% increase in revenue to C$100.9

Read More...
XORTX Therapeutics Files For Mixed Shelf Of Up To $50 Mln

XORTX Therapeutics Files For Mixed Shelf Of Up To $50 Mln

  • January 27, 2023 07:01 AM EST | Reuters

Jan 27 (Reuters) - XORTX Therapeutics Inc: * XORTX THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Further company coverage:

Read More...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK